Rosacea (Erythematotelangiectatic)
Investigational use for erythematotelangiectatic rosacea; case-series evidence for reduction in facial erythema.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for rosacea. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for rosacea is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Small case reports describe reduction of facial erythema in erythematotelangiectatic rosacea. There are no randomized controlled trials. Evidence-based first-line treatments include trigger avoidance, sun protection, topical brimonidine or oxymetazoline for erythema, topical metronidazole or ivermectin for inflammatory lesions, and vascular laser/IPL for telangiectasia.
- Hauptrisiken
- Bleeding from bite sites on the face for 6 to 24 hours after detachment
- Bruising and tenderness on visible facial skin for 5 to 10 days
- Itching and irritation at bite sites for days to weeks
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Hyperpigmentation or permanent small scars on the face at bite sites — cosmetically significant
- Worsening of inflammatory papulopustular lesions in some patients
- Wer dies nicht in Betracht ziehen sollte
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with active inflammatory rosacea flares with pustules
- Patients with ocular rosacea (involve ophthalmology; do not apply near eye)
- Patients with a tendency to keloid or hypertrophic scarring
- Patients prioritizing cosmetic outcome (visible facial scars possible)
- Was Sie Ihren Kliniker fragen sollten
- Have I been evaluated by a dermatologist?
- Have I trialed evidence-based therapies (topical brimonidine/oxymetazoline, metronidazole, ivermectin, vascular laser, IPL)?
- What evidence supports leech therapy for rosacea specifically?
- What is the realistic chance of benefit, and for how long?
- What is the risk of permanent facial scarring or hyperpigmentation?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- Wann dringende medizinische Versorgung suchen
- Spreading redness, warmth, pus, or red streaks on the face (facial cellulitis)
- Eye pain, vision change, or eye redness (ocular involvement)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is not FDA-cleared for rosacea.
- Case reports do NOT establish efficacy versus placebo or evidence-based topical and laser therapies.
- Mechanism rationale (vasoactive peptides) does NOT establish clinical efficacy.
- Facial leech placement carries cosmetic risk — small scars on visible skin are possible.
- Leech therapy is not a substitute for dermatology evaluation and standard topical/laser treatment.
Sicherheits-Querverweise
Clinical Profile
- Category
- dermatological
- ICD-10
- L71.0, L71.1, L71.8, L71.9
- Safety tier
- low
Evidence Summary
No controlled clinical trial of leech therapy for rosacea has been published, and there is no reliable case-series evidence of benefit. Any proposed mechanism (anti-inflammatory salivary peptides, local vascular effects) is speculative and unproven in this condition. Phymatous rosacea in particular would not be expected to respond. Standard treatments (topical brimonidine, oxymetazoline, ivermectin, azelaic acid, oral doxycycline, and vascular laser or intense pulsed light) remain first-line. ASH position: any use of leech therapy for rosacea is investigational and mechanistic only.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Almasi-Hashiani A et al. (2020), n=20
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Ocular rosacea with active blepharitis
- Recent (<6 weeks) facial laser or peel
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.